Ictal adipokines are associated with pain severity and treatment response in episodic migraine

Nu Cindy Chai, Bizu Gelaye, Gretchen E. Tietjen, Paul D. Dash, Barbara A. Gower, Linda W. White, Thomas N. Ward, Ann I. Scher, B. Lee Peterlin

Research output: Contribution to journalArticle

Abstract

Objective: To evaluate ictal adipokine levels in episodic migraineurs and their association with pain severity and treatment response. Methods: This was a double-blind, placebo-controlled trial evaluating peripheral blood specimens from episodic migraineurs at acute pain onset and 30 to 120 minutes after treatment with sumatriptan/naproxen sodium vs placebo. Total adiponectin (T-ADP), ADP multimers (high molecular weight [HMW], middle molecular weight, and low molecular weight [LMW]), leptin, and resistin levels were evaluated by immunoassays. Results: Thirty-four participants (17 responders, 17 nonresponders) were included. In all participants, pretreatment pain severity increased with every quartile increase in both the HMW:T-ADP ratio (coefficient of variation [CV] 0.51; 95% confidence interval [CI]: 0.08, 0.93; p 0.019) and resistin levels (CV 0.58; 95% CI: 0.21, 0.96; p 0.002), but was not associated with quartile changes in leptin levels. In responders, T-ADP (CV -0.98; 95% CI: -1.88, -0.08; p 0.031) and resistin (CV -0.95; 95% CI: -1.83, -0.07; p 0.034) levels decreased 120 minutes after treatment as compared with pretreatment. In addition, in responders, the HMW:T-ADP ratio (CV -0.04; 95% CI: -0.07, -0.01; p 0.041) decreased and the LMW:T-ADP ratio (CV 0.04; 95% CI: 0.01, 0.07; p 0.043) increased at 120 minutes after treatment. In nonresponders, the LMW:T-ADP ratio (CV -0.04; 95% CI: -0.07, -0.01; p 0.018) decreased 120 minutes after treatment. Leptin was not associated with treatment response. Conclusions: Both pretreatment migraine pain severity and treatment response are associated with changes in adipokine levels. Adipokines represent potential novel migraine biomarkers and drug targets.

Original languageEnglish (US)
Pages (from-to)1409-1418
Number of pages10
JournalNeurology
Volume84
Issue number14
DOIs
StatePublished - Apr 7 2015

Fingerprint

Adipokines
Migraine Disorders
Adiponectin
Molecular Weight
Stroke
Confidence Intervals
Pain
Resistin
Leptin
Therapeutics
Placebos
Naproxen
Acute Pain
Immunoassay
Adenosine Diphosphate
Biomarkers
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Chai, N. C., Gelaye, B., Tietjen, G. E., Dash, P. D., Gower, B. A., White, L. W., ... Peterlin, B. L. (2015). Ictal adipokines are associated with pain severity and treatment response in episodic migraine. Neurology, 84(14), 1409-1418. https://doi.org/10.1212/WNL.0000000000001443

Ictal adipokines are associated with pain severity and treatment response in episodic migraine. / Chai, Nu Cindy; Gelaye, Bizu; Tietjen, Gretchen E.; Dash, Paul D.; Gower, Barbara A.; White, Linda W.; Ward, Thomas N.; Scher, Ann I.; Peterlin, B. Lee.

In: Neurology, Vol. 84, No. 14, 07.04.2015, p. 1409-1418.

Research output: Contribution to journalArticle

Chai, NC, Gelaye, B, Tietjen, GE, Dash, PD, Gower, BA, White, LW, Ward, TN, Scher, AI & Peterlin, BL 2015, 'Ictal adipokines are associated with pain severity and treatment response in episodic migraine', Neurology, vol. 84, no. 14, pp. 1409-1418. https://doi.org/10.1212/WNL.0000000000001443
Chai NC, Gelaye B, Tietjen GE, Dash PD, Gower BA, White LW et al. Ictal adipokines are associated with pain severity and treatment response in episodic migraine. Neurology. 2015 Apr 7;84(14):1409-1418. https://doi.org/10.1212/WNL.0000000000001443
Chai, Nu Cindy ; Gelaye, Bizu ; Tietjen, Gretchen E. ; Dash, Paul D. ; Gower, Barbara A. ; White, Linda W. ; Ward, Thomas N. ; Scher, Ann I. ; Peterlin, B. Lee. / Ictal adipokines are associated with pain severity and treatment response in episodic migraine. In: Neurology. 2015 ; Vol. 84, No. 14. pp. 1409-1418.
@article{94f3223209924736974473e52e91b2d3,
title = "Ictal adipokines are associated with pain severity and treatment response in episodic migraine",
abstract = "Objective: To evaluate ictal adipokine levels in episodic migraineurs and their association with pain severity and treatment response. Methods: This was a double-blind, placebo-controlled trial evaluating peripheral blood specimens from episodic migraineurs at acute pain onset and 30 to 120 minutes after treatment with sumatriptan/naproxen sodium vs placebo. Total adiponectin (T-ADP), ADP multimers (high molecular weight [HMW], middle molecular weight, and low molecular weight [LMW]), leptin, and resistin levels were evaluated by immunoassays. Results: Thirty-four participants (17 responders, 17 nonresponders) were included. In all participants, pretreatment pain severity increased with every quartile increase in both the HMW:T-ADP ratio (coefficient of variation [CV] 0.51; 95{\%} confidence interval [CI]: 0.08, 0.93; p 0.019) and resistin levels (CV 0.58; 95{\%} CI: 0.21, 0.96; p 0.002), but was not associated with quartile changes in leptin levels. In responders, T-ADP (CV -0.98; 95{\%} CI: -1.88, -0.08; p 0.031) and resistin (CV -0.95; 95{\%} CI: -1.83, -0.07; p 0.034) levels decreased 120 minutes after treatment as compared with pretreatment. In addition, in responders, the HMW:T-ADP ratio (CV -0.04; 95{\%} CI: -0.07, -0.01; p 0.041) decreased and the LMW:T-ADP ratio (CV 0.04; 95{\%} CI: 0.01, 0.07; p 0.043) increased at 120 minutes after treatment. In nonresponders, the LMW:T-ADP ratio (CV -0.04; 95{\%} CI: -0.07, -0.01; p 0.018) decreased 120 minutes after treatment. Leptin was not associated with treatment response. Conclusions: Both pretreatment migraine pain severity and treatment response are associated with changes in adipokine levels. Adipokines represent potential novel migraine biomarkers and drug targets.",
author = "Chai, {Nu Cindy} and Bizu Gelaye and Tietjen, {Gretchen E.} and Dash, {Paul D.} and Gower, {Barbara A.} and White, {Linda W.} and Ward, {Thomas N.} and Scher, {Ann I.} and Peterlin, {B. Lee}",
year = "2015",
month = "4",
day = "7",
doi = "10.1212/WNL.0000000000001443",
language = "English (US)",
volume = "84",
pages = "1409--1418",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "14",

}

TY - JOUR

T1 - Ictal adipokines are associated with pain severity and treatment response in episodic migraine

AU - Chai, Nu Cindy

AU - Gelaye, Bizu

AU - Tietjen, Gretchen E.

AU - Dash, Paul D.

AU - Gower, Barbara A.

AU - White, Linda W.

AU - Ward, Thomas N.

AU - Scher, Ann I.

AU - Peterlin, B. Lee

PY - 2015/4/7

Y1 - 2015/4/7

N2 - Objective: To evaluate ictal adipokine levels in episodic migraineurs and their association with pain severity and treatment response. Methods: This was a double-blind, placebo-controlled trial evaluating peripheral blood specimens from episodic migraineurs at acute pain onset and 30 to 120 minutes after treatment with sumatriptan/naproxen sodium vs placebo. Total adiponectin (T-ADP), ADP multimers (high molecular weight [HMW], middle molecular weight, and low molecular weight [LMW]), leptin, and resistin levels were evaluated by immunoassays. Results: Thirty-four participants (17 responders, 17 nonresponders) were included. In all participants, pretreatment pain severity increased with every quartile increase in both the HMW:T-ADP ratio (coefficient of variation [CV] 0.51; 95% confidence interval [CI]: 0.08, 0.93; p 0.019) and resistin levels (CV 0.58; 95% CI: 0.21, 0.96; p 0.002), but was not associated with quartile changes in leptin levels. In responders, T-ADP (CV -0.98; 95% CI: -1.88, -0.08; p 0.031) and resistin (CV -0.95; 95% CI: -1.83, -0.07; p 0.034) levels decreased 120 minutes after treatment as compared with pretreatment. In addition, in responders, the HMW:T-ADP ratio (CV -0.04; 95% CI: -0.07, -0.01; p 0.041) decreased and the LMW:T-ADP ratio (CV 0.04; 95% CI: 0.01, 0.07; p 0.043) increased at 120 minutes after treatment. In nonresponders, the LMW:T-ADP ratio (CV -0.04; 95% CI: -0.07, -0.01; p 0.018) decreased 120 minutes after treatment. Leptin was not associated with treatment response. Conclusions: Both pretreatment migraine pain severity and treatment response are associated with changes in adipokine levels. Adipokines represent potential novel migraine biomarkers and drug targets.

AB - Objective: To evaluate ictal adipokine levels in episodic migraineurs and their association with pain severity and treatment response. Methods: This was a double-blind, placebo-controlled trial evaluating peripheral blood specimens from episodic migraineurs at acute pain onset and 30 to 120 minutes after treatment with sumatriptan/naproxen sodium vs placebo. Total adiponectin (T-ADP), ADP multimers (high molecular weight [HMW], middle molecular weight, and low molecular weight [LMW]), leptin, and resistin levels were evaluated by immunoassays. Results: Thirty-four participants (17 responders, 17 nonresponders) were included. In all participants, pretreatment pain severity increased with every quartile increase in both the HMW:T-ADP ratio (coefficient of variation [CV] 0.51; 95% confidence interval [CI]: 0.08, 0.93; p 0.019) and resistin levels (CV 0.58; 95% CI: 0.21, 0.96; p 0.002), but was not associated with quartile changes in leptin levels. In responders, T-ADP (CV -0.98; 95% CI: -1.88, -0.08; p 0.031) and resistin (CV -0.95; 95% CI: -1.83, -0.07; p 0.034) levels decreased 120 minutes after treatment as compared with pretreatment. In addition, in responders, the HMW:T-ADP ratio (CV -0.04; 95% CI: -0.07, -0.01; p 0.041) decreased and the LMW:T-ADP ratio (CV 0.04; 95% CI: 0.01, 0.07; p 0.043) increased at 120 minutes after treatment. In nonresponders, the LMW:T-ADP ratio (CV -0.04; 95% CI: -0.07, -0.01; p 0.018) decreased 120 minutes after treatment. Leptin was not associated with treatment response. Conclusions: Both pretreatment migraine pain severity and treatment response are associated with changes in adipokine levels. Adipokines represent potential novel migraine biomarkers and drug targets.

UR - http://www.scopus.com/inward/record.url?scp=84926609308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926609308&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000001443

DO - 10.1212/WNL.0000000000001443

M3 - Article

C2 - 25746563

AN - SCOPUS:84926609308

VL - 84

SP - 1409

EP - 1418

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 14

ER -